CRIS Current Research Information System

MARTELLO, MARINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.613
NA - Nord America 3.256
EU - Europa 2.191
AF - Africa 248
SA - Sud America 184
Continente sconosciuto - Info sul continente non disponibili 167
OC - Oceania 3
Totale 9.662
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.153
VN - Vietnam 1.121
CN - Cina 863
SG - Singapore 842
IT - Italia 775
GB - Regno Unito 299
DE - Germania 236
HK - Hong Kong 219
SE - Svezia 180
IN - India 148
NL - Olanda 141
BR - Brasile 131
FR - Francia 130
KR - Corea 115
BD - Bangladesh 91
RU - Federazione Russa 88
CI - Costa d'Avorio 85
IE - Irlanda 69
FI - Finlandia 55
CA - Canada 48
JP - Giappone 46
SC - Seychelles 43
TG - Togo 40
ZA - Sudafrica 37
PH - Filippine 30
AT - Austria 27
BG - Bulgaria 27
CH - Svizzera 27
AR - Argentina 26
UA - Ucraina 25
MX - Messico 23
PL - Polonia 23
NG - Nigeria 22
EE - Estonia 20
ES - Italia 19
TH - Thailandia 19
ID - Indonesia 18
BE - Belgio 17
TW - Taiwan 14
IQ - Iraq 11
JO - Giordania 11
TR - Turchia 11
IR - Iran 10
EC - Ecuador 9
JM - Giamaica 9
RO - Romania 8
SA - Arabia Saudita 8
CO - Colombia 6
GT - Guatemala 6
DZ - Algeria 5
SV - El Salvador 5
CL - Cile 4
CY - Cipro 4
CZ - Repubblica Ceca 4
GR - Grecia 4
PK - Pakistan 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
HN - Honduras 3
HR - Croazia 3
LT - Lituania 3
NO - Norvegia 3
OM - Oman 3
PT - Portogallo 3
TT - Trinidad e Tobago 3
UZ - Uzbekistan 3
VE - Venezuela 3
AO - Angola 2
AU - Australia 2
AZ - Azerbaigian 2
CR - Costa Rica 2
EG - Egitto 2
GE - Georgia 2
IL - Israele 2
KE - Kenya 2
KH - Cambogia 2
KZ - Kazakistan 2
LB - Libano 2
PS - Palestinian Territory 2
RS - Serbia 2
UY - Uruguay 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GA - Gabon 1
GH - Ghana 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LC - Santa Lucia 1
MA - Marocco 1
MD - Moldavia 1
MN - Mongolia 1
NC - Nuova Caledonia 1
NI - Nicaragua 1
NP - Nepal 1
PA - Panama 1
PE - Perù 1
PY - Paraguay 1
Totale 9.492
Salva come PNG Salva come JPEG
Città #
Singapore 583
Ashburn 392
Ho Chi Minh City 311
Chandler 260
Southend 241
Hanoi 240
Hefei 240
Hong Kong 214
San Jose 212
Dallas 205
Fairfield 189
Bologna 178
Ann Arbor 119
Seoul 108
Beijing 98
New York 88
Abidjan 85
Houston 85
Woodbridge 79
Wilmington 78
Seattle 71
Dublin 69
Cambridge 66
Los Angeles 65
Princeton 64
Milan 61
Santa Clara 58
Council Bluffs 55
Lauterbourg 53
Boardman 51
Haiphong 44
Helsinki 43
Lomé 40
Hyderabad 39
Dong Ket 38
Tokyo 38
Munich 36
Nanjing 31
Bremen 30
Rome 29
Da Nang 27
Frankfurt am Main 26
Sofia 26
São Paulo 25
Amsterdam 24
Buffalo 24
Fabriano 23
Turin 23
Westminster 23
Bengaluru 22
Padova 20
Salsomaggiore Terme 20
Vienna 20
Abeokuta 19
Berlin 19
Guangzhou 18
Toronto 18
Biên Hòa 17
Can Tho 17
Brussels 16
Warsaw 16
Ha Long 15
Redondo Beach 15
Bern 14
Nuremberg 14
Quận Bình Thạnh 14
Redmond 14
Shanghai 14
Shenyang 14
Medford 13
Thái Nguyên 13
Hải Dương 12
London 12
Naples 12
Ninh Bình 12
Redwood City 12
Saint Petersburg 12
Wuhan 12
Amman 11
Changsha 11
Falkenstein 11
Florence 11
Jakarta 11
Jinan 11
Tianjin 11
Johannesburg 10
Nanchang 10
Orem 10
Quận Một 10
Chicago 9
Lappeenranta 9
Modena 9
Mondolfo 9
Phoenix 9
San Francisco 9
Zhengzhou 9
Brooklyn 8
Bắc Ninh 8
Bến Tre 8
Dhaka 8
Totale 5.865
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 719
BoBafit: A copy number clustering tool designed to refit and recalibrate the baseline region of tumors’ profiles 335
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 238
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 237
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 231
A 41-gene signature predicts complete response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) as induction therapy prior to autologous stem-cell transplantation (ASCT) in multiple myeloma (MM). 226
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 221
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. 218
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 213
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 213
Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients 210
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients 208
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 206
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 205
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 205
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 201
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. 199
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 194
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 188
NEXT GENERATION SEQUENCING FOR MINIMAL RESIDUAL DISEASE MEASUREMENT IN THE DAILY CLINICAL MANAGEMENT OF PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS IS FEASIBLE AND PROVIDES USEFUL CLINICAL DATA. 185
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 184
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 182
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma 178
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 177
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 176
A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM) 176
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients 172
HIF-1a INHIBITION PROMOTES CELL CYCLE ARREST IN MULTIPLE MYELOMA 171
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 169
Genomic characterization of the putative myeloma stem cells clone reveals alterations possibly correlated with the origin of disease. 165
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 164
OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma 160
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation 159
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 158
A Methodologically Updated De-Novo Extraction of Copy Number Signatures in Multiple Myeloma: Clinical Significance and Putative Aetiologies 156
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 156
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 155
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients 146
VarianThinker: a classification method to confidently approach the mutation heterogeneity in Multiple Myeloma 146
Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma 143
Rare, but complex chromosomal rearrangements, defined "Chromoanagenesis”, caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients 142
Overview of 1q abnormalities in multiple myeloma: scientific opinions from Italian experts 136
SIRT regulates the molecular interaction between c-MYC and HIF-1 alpha in multiple myeloma 136
Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4 134
Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma 133
COMPARISON BETWEEN NGS IGH/TCR AND RT-PCR BCR::ABL1 MINIMAL RESIDUAL DISEASE IN PH+ ACUTE LYMPHOBLASTIC LEUKEMIA: A PRELIMINARY ANALYSIS 118
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 115
OAB-057: Temporal-weight estimation of the copy number alterations of of 1384 Multiple Myeloma patients defines an ancestrality index impacting patients survival 97
Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies? 94
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma 92
IMPLEMENTATION OF NEXT GENERATION SEQUENCING AS BEST TOOL FOR ROUTINE EVALUATION OF MINIMAL RESIDUAL DISEASE IN THE DAILY PRACTICE OF MULTIPLE MYELOMA PATIENTS 88
Monoclonal and polyclonal circulating plasma cells (CPCs) are linked to disease spread in multiple myeloma 77
Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives 66
Undetectable Minimal Residual Disease in Multiple Myeloma: Bridging the Gap Between Clinical Trials and Real-life Application 48
Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time? 41
Totale 9.662
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.003
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.003
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022684 0 41 37 53 61 39 25 47 40 91 115 135
2022/20231.025 91 135 40 164 79 75 28 56 151 46 81 79
2023/2024473 38 46 42 38 30 94 24 84 14 19 24 20
2024/20251.363 98 132 112 110 121 61 111 57 30 156 126 249
2025/20264.495 356 963 350 319 367 174 361 166 803 258 220 158
2026/2027283 131 152 0 0 0 0 0 0 0 0 0 0
Totale 9.662